Stifel raised the firm’s price target on Globus Medical to $64 from $61 and keeps a Buy rating on the shares. The company recently reported Q4 results provided a more-complete picture after the pre-announced/guidance provided in January, the analyst tells investors. Overall, the firm has more conviction in its bullish thesis and modeling, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GMED:
- Globus Medical Reports Fourth Quarter and Full Year 2023 Results
- Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call
- Globus Medical Promotes Keith Pfeil to COO and CFO
- Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial Officer
- Globus Medical promotes Keith Pfeil as COO and Chief Financial Officer
